# Comprehensive impact of Intermittent Hypoxia Training and Intermittent Fasting on metabolic and cognitive health in adults with obesity: an umbrella systematic review and meta-analysis

**Authors:** Jiajia Guo, Ning Zhang, Juan Chen, Xueyu Liu

PMC · DOI: 10.3389/fnut.2025.1664600 · Frontiers in Nutrition · 2025-10-15

## TL;DR

This study finds that combining intermittent hypoxia training and intermittent fasting can improve weight loss and cognitive function in adults with obesity.

## Contribution

The study is the first to comprehensively evaluate the combined effects of intermittent hypoxia training and intermittent fasting on both metabolic and cognitive health in obese adults.

## Key findings

- Combined IHT and IF led to significant weight loss of 6.3 kg on average.
- Cognitive improvements were observed in memory and attention domains.
- The study highlights the need for long-term research due to methodological heterogeneity.

## Abstract

Obesity has emerged as a global health crisis, posing significant challenges to metabolic function and cognitive health. It is associated with insulin resistance, elevated triglycerides, and reduced HDL cholesterol levels. Cognitive decline in obesity involves multifactorial pathways including neuroinflammation, vascular dysfunction, and blood–brain barrier disruption. Intermittent Hypoxia Training (IHT) and Intermittent Fasting (IF) have shown promise as non-pharmacological interventions for these obesity-related issues.

This systematic review and meta-analysis aim to evaluate the effects of IHT, IF, and their combination on metabolic markers (insulin sensitivity, lipid profiles, glucose levels) and specific cognitive domains (memory, executive function, attention) and cognitive function in obese adults.

The analysis encompassed studies published from October 2014 onward, sourced from PubMed, Web of Science, Scopus, and other relevant databases. The inclusion criteria were randomized controlled trials and non-randomized comparative studies focusing on IHT, IF, or their combination. Study quality was assessed using the Newcastle-Ottawa Scale and the Cochrane risk bias tool. Data synthesis was performed using a random-effects model, with heterogeneity assessed via I2 statistics.

The review included 28 studies involving 2,134 participants, followed up for an average of 12 weeks. Among these, 15 were RCTs and 13 were observational studies. The participants had a mean age of 45 ± 12 years, with 60% being female. The combined IHT and IF intervention demonstrated superior benefits, with significant weight loss (mean reduction: 6.3 kg, 95% CI: −8.2 to −4.5 kg). Cognitive performance showed domain-specific improvements: memory (SMD = 0.60, 95% CI: 0.43–0.77) and attention (SMD = 0.57, 95% CI: 0.40–0.74), though with significant heterogeneity (I2 > 50%). Egger’s test indicated minimal publication bias (p = 0.18).

Our meta-analysis reveals that IHT and IF may serve as promising non-drug strategies for improving metabolic and cognitive outcomes in adults with obesity. Given the short-term evidence and methodological heterogeneity, long-term studies are needed to confirm these findings.

## Linked entities

- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** Obesity (MESH:D009765), Cognitive decline (MESH:D003072), insulin resistance (MESH:D007333), vascular dysfunction (MESH:D002561), neuroinflammation (MESH:D000090862), Hypoxia (MESH:D000860), weight loss (MESH:D015431)
- **Chemicals:** lipid (MESH:D008055), triglycerides (MESH:D014280), glucose (MESH:D005947)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12568350/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12568350/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC12568350/full.md

---
Source: https://tomesphere.com/paper/PMC12568350